[
  {
    "column": "S6",
    "description": "S6: How many years have you been in clinical practice, post residency/training?",
    "level": "parent",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "NA",
    "context": ""
  },
  {
    "column": "S8r1",
    "description": "S8r1: Treating/Managing patients - Approximately what percentage of your professional time is spent performing each of the following activities?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "S8",
    "context": ""
  },
  {
    "column": "S8r2",
    "description": "S8r2: Performing academic functions (e.g. teaching, publishing) - Approximately what percentage of your professional time is spent performing each of the following activities?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "S8",
    "context": ""
  },
  {
    "column": "S8r3",
    "description": "S8r3: Participating in clinical research - Approximately what percentage of your professional time is spent performing each of the following activities?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "S8",
    "context": ""
  },
  {
    "column": "S8r4",
    "description": "S8r4: Performing other functions - Approximately what percentage of your professional time is spent performing each of the following activities?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "S8",
    "context": ""
  },
  {
    "column": "S10",
    "description": "S10: Using your best estimate, how many adult patients, age 18 or older, do you personally manage in your practice in a month? By ‘personally’, we mean patients for whom you are a primary treatment decision maker.",
    "level": "parent",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "NA",
    "context": ""
  },
  {
    "column": "S11",
    "description": "S11: Of those [pipe:S10] adult patients for whom you are the primary treatment decision maker, roughly how many have a confirmed diagnosis of hypercholesterolemia with established cardiovascular disease (CVD)?",
    "level": "parent",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "NA",
    "context": ""
  },
  {
    "column": "S12r1",
    "description": "S12r1: Over 5 years ago - Of those, how many patients have had an event (MI, CAD, coronary revascularization, stent placement, etc.) …",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "S12",
    "context": ""
  },
  {
    "column": "S12r2",
    "description": "S12r2: Within the last 3-5 years - Of those, how many patients have had an event (MI, CAD, coronary revascularization, stent placement, etc.) …",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "S12",
    "context": ""
  },
  {
    "column": "S12r3",
    "description": "S12r3: Within the 1-2 years - Of those, how many patients have had an event (MI, CAD, coronary revascularization, stent placement, etc.) …",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "S12",
    "context": ""
  },
  {
    "column": "S12r4",
    "description": "S12r4: Within the last year - Of those, how many patients have had an event (MI, CAD, coronary revascularization, stent placement, etc.) …",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "S12",
    "context": ""
  },
  {
    "column": "A1r1",
    "description": "A1r1: High cholesterol (elevated LDL-C) - Knowing these health issues are all important, if you had to prioritize importance to a patient’s overall risk profile, how would you rank the following:",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A1",
    "context": ""
  },
  {
    "column": "A1r2",
    "description": "A1r2: Hypertension - Knowing these health issues are all important, if you had to prioritize importance to a patient’s overall risk profile, how would you rank the following:",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A1",
    "context": ""
  },
  {
    "column": "A1r3",
    "description": "A1r3: Diabetes - Knowing these health issues are all important, if you had to prioritize importance to a patient’s overall risk profile, how would you rank the following:",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A1",
    "context": ""
  },
  {
    "column": "A1r4",
    "description": "A1r4: Atrial fibrillation - Knowing these health issues are all important, if you had to prioritize importance to a patient’s overall risk profile, how would you rank the following:",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A1",
    "context": ""
  },
  {
    "column": "A1r5",
    "description": "A1r5: Unstable angina - Knowing these health issues are all important, if you had to prioritize importance to a patient’s overall risk profile, how would you rank the following:",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A1",
    "context": ""
  },
  {
    "column": "A1r6",
    "description": "A1r6: Obesity (BMI > 30) - Knowing these health issues are all important, if you had to prioritize importance to a patient’s overall risk profile, how would you rank the following:",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A1",
    "context": ""
  },
  {
    "column": "A1r7",
    "description": "A1r7: Lipoprotein(a) (Lp(a)) - Knowing these health issues are all important, if you had to prioritize importance to a patient’s overall risk profile, how would you rank the following:",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A1",
    "context": ""
  },
  {
    "column": "A1r8",
    "description": "A1r8: Apolipoprotein B (ApoB) - Knowing these health issues are all important, if you had to prioritize importance to a patient’s overall risk profile, how would you rank the following:",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A1",
    "context": ""
  },
  {
    "column": "A4r1",
    "description": "A4r1: Diet & exercise alone - What % of your patients are able to control their LDL-C with …? Again, “patients” throughout refers to those diagnosed with hypercholesterolemia with established cardiovascular disease (CVD) who have had an event (MI, C",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A4",
    "context": ""
  },
  {
    "column": "A4r2",
    "description": "A4r2: Statin monotherapy (plus diet & exercise) - What % of your patients are able to control their LDL-C with …? Again, “patients” throughout refers to those diagnosed with hypercholesterolemia with established cardiovascular disease (CVD) who have",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A4",
    "context": ""
  },
  {
    "column": "A4r3",
    "description": "A4r3: Other oral therapies (including ezetimibe, Nexletol/Nexlizet, etc.), with or without statins (plus diet & exercise) - What % of your patients are able to control their LDL-C with …? Again, “patients” throughout refers to those diagnosed with h",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A4",
    "context": ""
  },
  {
    "column": "A4r4",
    "description": "A4r4: Self-administered injectable therapy (e.g., Repatha, Praluent) (plus diet & exercise) - What % of your patients are able to control their LDL-C with …? Again, “patients” throughout refers to those diagnosed with hypercholesterolemia with estab",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A4",
    "context": ""
  },
  {
    "column": "A4r5",
    "description": "A4r5: HCP-administered injectable therapy (e.g., Leqvio) (plus diet & exercise) - What % of your patients are able to control their LDL-C with …? Again, “patients” throughout refers to those diagnosed with hypercholesterolemia with established cardi",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A4",
    "context": ""
  },
  {
    "column": "A6r1",
    "description": "A6r1: Leqvio (inclisiran) - Thinking of your NEXT 100 patients who require therapy in addition to statins to lower LDL-C and/or to reduce the risk of future CV events, for how many would you prescribe each of the following treatments? Again, “patients",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A6",
    "context": ""
  },
  {
    "column": "A6r2",
    "description": "A6r2: Praluent (alirocumab) - Thinking of your NEXT 100 patients who require therapy in addition to statins to lower LDL-C and/or to reduce the risk of future CV events, for how many would you prescribe each of the following treatments? Again, “patients",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A6",
    "context": ""
  },
  {
    "column": "A6r3",
    "description": "A6r3: Repatha (evolocumab) - Thinking of your NEXT 100 patients who require therapy in addition to statins to lower LDL-C and/or to reduce the risk of future CV events, for how many would you prescribe each of the following treatments? Again, “patients",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A6",
    "context": ""
  },
  {
    "column": "A6r4",
    "description": "A6r4: Zetia (ezetimibe) or generic - Thinking of your NEXT 100 patients who require therapy in addition to statins to lower LDL-C and/or to reduce the risk of future CV events, for how many would you prescribe each of the following treatments? Again, “p",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A6",
    "context": ""
  },
  {
    "column": "A6r5",
    "description": "A6r5: Nexletol (bempedoic acid) or Nexlizet (bempedoic acid and ezetimibe) - Thinking of your NEXT 100 patients who require therapy in addition to statins to lower LDL-C and/or to reduce the risk of future CV events, for how many would you prescribe each",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A6",
    "context": ""
  },
  {
    "column": "A6r13",
    "description": "A6r13: Other - Thinking of your NEXT 100 patients who require therapy in addition to statins to lower LDL-C and/or to reduce the risk of future CV events, for how many would you prescribe each of the following treatments? Again, “patients” throughout",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A6",
    "context": ""
  },
  {
    "column": "A6r14",
    "description": "A6r14: No additional therapy beyond statins - Thinking of your NEXT 100 patients who require therapy in addition to statins to lower LDL-C and/or to reduce the risk of future CV events, for how many would you prescribe each of the following treatments? Ag",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "A6",
    "context": ""
  },
  {
    "column": "B4r1",
    "description": "B4r1: Within 2 weeks of CV event - Thinking of the typical 10 patients of yours who have experienced a CV event, for how many do you adjust their LDL-C lowering therapy…",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "B4",
    "context": ""
  },
  {
    "column": "B4r2",
    "description": "B4r2: Within 1 month of CV event - Thinking of the typical 10 patients of yours who have experienced a CV event, for how many do you adjust their LDL-C lowering therapy…",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "B4",
    "context": ""
  },
  {
    "column": "B4r3",
    "description": "B4r3: Within 3 months of CV event - Thinking of the typical 10 patients of yours who have experienced a CV event, for how many do you adjust their LDL-C lowering therapy…",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "B4",
    "context": ""
  },
  {
    "column": "B4r4",
    "description": "B4r4: More than 3 months after CV event - Thinking of the typical 10 patients of yours who have experienced a CV event, for how many do you adjust their LDL-C lowering therapy…",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "B4",
    "context": ""
  },
  {
    "column": "B4r5",
    "description": "B4r5: Did not adjust LDL-C treatment - Thinking of the typical 10 patients of yours who have experienced a CV event, for how many do you adjust their LDL-C lowering therapy…",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "B4",
    "context": ""
  },
  {
    "column": "B7_1r1",
    "description": "B7_1r1: Efficacy in lowering LDL-C - Please think about your “typical” conversation with a patient when you are first offering the advanced therapy below. Select the topics in the order that you typically discuss them with the patient. You can skip to",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "B7_1",
    "context": ""
  },
  {
    "column": "B7_1r2",
    "description": "B7_1r2: Efficacy in reducing risk of cardiovascular events - Please think about your “typical” conversation with a patient when you are first offering the advanced therapy below. Select the topics in the order that you typically discuss them with the",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "B7_1",
    "context": ""
  },
  {
    "column": "B7_1r3",
    "description": "B7_1r3: Safety/tolerability - Please think about your “typical” conversation with a patient when you are first offering the advanced therapy below. Select the topics in the order that you typically discuss them with the patient. You can skip topics yo",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "B7_1",
    "context": ""
  },
  {
    "column": "B7_1r4",
    "description": "B7_1r4: How the treatment is administered (e.g., injectable vs. oral) - Please think about your “typical” conversation with a patient when you are first offering the advanced therapy below. Select the topics in the order that you typically discuss the",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "B7_1",
    "context": ""
  },
  {
    "column": "B7_1r5",
    "description": "B7_1r5: How often the treatment is administered - Please think about your “typical” conversation with a patient when you are first offering the advanced therapy below. Select the topics in the order that you typically discuss them with the patient. Yo",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "B7_1",
    "context": ""
  },
  {
    "column": "B7_1r6",
    "description": "B7_1r6: Who administers the treatment (e.g., self- vs. HCP- administered) - Please think about your “typical” conversation with a patient when you are first offering the advanced therapy below. Select the topics in the order that you typically discuss",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "B7_1",
    "context": ""
  },
  {
    "column": "B7_1r7",
    "description": "B7_1r7: Insurance coverage - Please think about your “typical” conversation with a patient when you are first offering the advanced therapy below. Select the topics in the order that you typically discuss them with the patient. You can skip topics you",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "B7_1",
    "context": ""
  },
  {
    "column": "B7_1r8",
    "description": "B7_1r8: Expected cost to the patient - Please think about your “typical” conversation with a patient when you are first offering the advanced therapy below. Select the topics in the order that you typically discuss them with the patient. You can skip",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "B7_1",
    "context": ""
  },
  {
    "column": "B7_1r9",
    "description": "B7_1r9: Years on the market - Please think about your “typical” conversation with a patient when you are first offering the advanced therapy below. Select the topics in the order that you typically discuss them with the patient. You can skip topics yo",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "B7_1",
    "context": ""
  },
  {
    "column": "B7_1r10",
    "description": "B7_1r10: Your level of experience prescribing that treatment - Please think about your “typical” conversation with a patient when you are first offering the advanced therapy below. Select the topics in the order that you typically discuss them with th",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "B7_1",
    "context": ""
  },
  {
    "column": "B7_1r11",
    "description": "B7_1r11: That the treatment is strongly recommended by guidelines or experts in the field - Please think about your “typical” conversation with a patient when you are first offering the advanced therapy below. Select the topics in the order that you t",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "B7_1",
    "context": ""
  },
  {
    "column": "B7_1r12",
    "description": "B7_1r12: Feedback from your patients - Please think about your “typical” conversation with a patient when you are first offering the advanced therapy below. Select the topics in the order that you typically discuss them with the patient. You can skip",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "B7_1",
    "context": ""
  },
  {
    "column": "B7_2r1",
    "description": "B7_2r1: Efficacy in lowering LDL-C - Please think about your “typical” conversation with a patient when you are first offering the advanced therapy below. Select the topics in the order that you typically discuss them with the patient. You can skip to",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "B7_2",
    "context": ""
  },
  {
    "column": "B7_2r2",
    "description": "B7_2r2: Efficacy in reducing risk of cardiovascular events - Please think about your “typical” conversation with a patient when you are first offering the advanced therapy below. Select the topics in the order that you typically discuss them with the",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "B7_2",
    "context": ""
  },
  {
    "column": "B7_2r3",
    "description": "B7_2r3: Safety/tolerability - Please think about your “typical” conversation with a patient when you are first offering the advanced therapy below. Select the topics in the order that you typically discuss them with the patient. You can skip topics yo",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "B7_2",
    "context": ""
  },
  {
    "column": "B7_2r4",
    "description": "B7_2r4: How the treatment is administered (e.g., injectable vs. oral) - Please think about your “typical” conversation with a patient when you are first offering the advanced therapy below. Select the topics in the order that you typically discuss the",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "B7_2",
    "context": ""
  },
  {
    "column": "B7_2r5",
    "description": "B7_2r5: How often the treatment is administered - Please think about your “typical” conversation with a patient when you are first offering the advanced therapy below. Select the topics in the order that you typically discuss them with the patient. Yo",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "B7_2",
    "context": ""
  },
  {
    "column": "B7_2r6",
    "description": "B7_2r6: Who administers the treatment (e.g., self- vs. HCP- administered) - Please think about your “typical” conversation with a patient when you are first offering the advanced therapy below. Select the topics in the order that you typically discuss",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "B7_2",
    "context": ""
  },
  {
    "column": "B7_2r7",
    "description": "B7_2r7: Insurance coverage - Please think about your “typical” conversation with a patient when you are first offering the advanced therapy below. Select the topics in the order that you typically discuss them with the patient. You can skip topics you",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "B7_2",
    "context": ""
  },
  {
    "column": "B7_2r8",
    "description": "B7_2r8: Expected cost to the patient - Please think about your “typical” conversation with a patient when you are first offering the advanced therapy below. Select the topics in the order that you typically discuss them with the patient. You can skip",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "B7_2",
    "context": ""
  },
  {
    "column": "B7_2r9",
    "description": "B7_2r9: Years on the market - Please think about your “typical” conversation with a patient when you are first offering the advanced therapy below. Select the topics in the order that you typically discuss them with the patient. You can skip topics yo",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "B7_2",
    "context": ""
  },
  {
    "column": "B7_2r10",
    "description": "B7_2r10: Your level of experience prescribing that treatment - Please think about your “typical” conversation with a patient when you are first offering the advanced therapy below. Select the topics in the order that you typically discuss them with th",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "B7_2",
    "context": ""
  },
  {
    "column": "B7_2r11",
    "description": "B7_2r11: That the treatment is strongly recommended by guidelines or experts in the field - Please think about your “typical” conversation with a patient when you are first offering the advanced therapy below. Select the topics in the order that you t",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "B7_2",
    "context": ""
  },
  {
    "column": "B7_2r12",
    "description": "B7_2r12: Feedback from your patients - Please think about your “typical” conversation with a patient when you are first offering the advanced therapy below. Select the topics in the order that you typically discuss them with the patient. You can skip",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "B7_2",
    "context": ""
  },
  {
    "column": "D4r1",
    "description": "D4r1: Below age 45 - Please indicate the approximate age distribution for your [res patients].",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "D4",
    "context": ""
  },
  {
    "column": "D4r2",
    "description": "D4r2: Age 45 – 64 - Please indicate the approximate age distribution for your [res patients].",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "D4",
    "context": ""
  },
  {
    "column": "D4r3",
    "description": "D4r3: 65 and older - Please indicate the approximate age distribution for your [res patients].",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "D4",
    "context": ""
  },
  {
    "column": "D5r1",
    "description": "D5r1: Woman - Please indicate the gender distribution for your [res patients].",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "D5",
    "context": ""
  },
  {
    "column": "D5r2",
    "description": "D5r2: Man - Please indicate the gender distribution for your [res patients].",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "D5",
    "context": ""
  },
  {
    "column": "D5r4",
    "description": "D5r4: Other / not sure - Please indicate the gender distribution for your [res patients].",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "D5",
    "context": ""
  },
  {
    "column": "D6r1",
    "description": "D6r1: Asian - To the best of your knowledge, what is the approximate distribution of racial background of your [res patients].",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "D6",
    "context": ""
  },
  {
    "column": "D6r2",
    "description": "D6r2: Black or African American - To the best of your knowledge, what is the approximate distribution of racial background of your [res patients].",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "D6",
    "context": ""
  },
  {
    "column": "D6r3",
    "description": "D6r3: Native American or Alaskan Native - To the best of your knowledge, what is the approximate distribution of racial background of your [res patients].",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "D6",
    "context": ""
  },
  {
    "column": "D6r4",
    "description": "D6r4: Native Hawaiian or Other Pacific Islander - To the best of your knowledge, what is the approximate distribution of racial background of your [res patients].",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "D6",
    "context": ""
  },
  {
    "column": "D6r5",
    "description": "D6r5: White - To the best of your knowledge, what is the approximate distribution of racial background of your [res patients].",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "D6",
    "context": ""
  },
  {
    "column": "D6r6",
    "description": "D6r6: Other, please specify - To the best of your knowledge, what is the approximate distribution of racial background of your [res patients].",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "D6",
    "context": ""
  },
  {
    "column": "D6a",
    "description": "D6a: Approximately what % of your [res patients] are Hispanic, Latinx, or of Spanish origin?",
    "level": "parent",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "NA",
    "context": ""
  },
  {
    "column": "D8r1",
    "description": "D8r1: No coverage / cash paying - What percent of your [res patients] have the following as their primary healthcare coverage?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "D8",
    "context": ""
  },
  {
    "column": "D8r2",
    "description": "D8r2: Commercial insurance (HMO, PPO, or other private insurance – may be a Medicare supplement) - What percent of your [res patients] have the following as their primary healthcare coverage?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "D8",
    "context": ""
  },
  {
    "column": "D8r3",
    "description": "D8r3: Medicaid / Public Aid - What percent of your [res patients] have the following as their primary healthcare coverage?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "D8",
    "context": ""
  },
  {
    "column": "D8r4",
    "description": "D8r4: Traditional Medicare - What percent of your [res patients] have the following as their primary healthcare coverage?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "D8",
    "context": ""
  },
  {
    "column": "D8r5",
    "description": "D8r5: Medicare Advantage - What percent of your [res patients] have the following as their primary healthcare coverage?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "D8",
    "context": ""
  },
  {
    "column": "D8r6",
    "description": "D8r6: VA (Veterans’ Administration) or Department of Defense - What percent of your [res patients] have the following as their primary healthcare coverage?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "D8",
    "context": ""
  },
  {
    "column": "D8r7",
    "description": "D8r7: Other - What percent of your [res patients] have the following as their primary healthcare coverage?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "D8",
    "context": ""
  },
  {
    "column": "F1",
    "description": "F1: On average, how many hours per week in total do you spend on keeping abreast of medical developments or medical education, specifically in cardiovascular disease? This would include (but not limited to) any of the following activities: reading medical",
    "level": "parent",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "NA",
    "context": ""
  },
  {
    "column": "F2",
    "description": "F2: In the past year, how many medical conferences or seminars (including online/virtual) related to cardiovascular disease did you attend?",
    "level": "parent",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "NA",
    "context": ""
  },
  {
    "column": "F4r1",
    "description": "F4r1: Interactions with sales representatives - From which sources would you be most receptive to receiving information on new treatments for cardiovascular disease?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "F4",
    "context": ""
  },
  {
    "column": "F4r2",
    "description": "F4r2: Interactions with Medical Science Liaisons - From which sources would you be most receptive to receiving information on new treatments for cardiovascular disease?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "F4",
    "context": ""
  },
  {
    "column": "F4r3",
    "description": "F4r3: Seminars / conferences (with or without CME credit) - From which sources would you be most receptive to receiving information on new treatments for cardiovascular disease?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "F4",
    "context": ""
  },
  {
    "column": "F4r4",
    "description": "F4r4: Video-conferences / webcasts - From which sources would you be most receptive to receiving information on new treatments for cardiovascular disease?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "F4",
    "context": ""
  },
  {
    "column": "F4r5",
    "description": "F4r5: Podcasts - From which sources would you be most receptive to receiving information on new treatments for cardiovascular disease?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "F4",
    "context": ""
  },
  {
    "column": "F4r6",
    "description": "F4r6: Dinner meetings / roundtable discussions - From which sources would you be most receptive to receiving information on new treatments for cardiovascular disease?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "F4",
    "context": ""
  },
  {
    "column": "F4r7",
    "description": "F4r7: Electronic detailing / e-detailing (sales presentation online or via phone) - From which sources would you be most receptive to receiving information on new treatments for cardiovascular disease?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "F4",
    "context": ""
  },
  {
    "column": "F4r8",
    "description": "F4r8: Medical information call centers sponsored by pharma / biotech companies - From which sources would you be most receptive to receiving information on new treatments for cardiovascular disease?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "F4",
    "context": ""
  },
  {
    "column": "F4r9",
    "description": "F4r9: Medical / disease specific websites - From which sources would you be most receptive to receiving information on new treatments for cardiovascular disease?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "F4",
    "context": ""
  },
  {
    "column": "F4r10",
    "description": "F4r10: Influential peers or specialists in the field - From which sources would you be most receptive to receiving information on new treatments for cardiovascular disease?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "F4",
    "context": ""
  },
  {
    "column": "F4r11",
    "description": "F4r11: Internet educational platforms (without CME credit) - From which sources would you be most receptive to receiving information on new treatments for cardiovascular disease?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "F4",
    "context": ""
  },
  {
    "column": "F4r12",
    "description": "F4r12: Audio/teleconferences with clinical speaker - From which sources would you be most receptive to receiving information on new treatments for cardiovascular disease?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "F4",
    "context": ""
  },
  {
    "column": "F4r13",
    "description": "F4r13: CME programs - From which sources would you be most receptive to receiving information on new treatments for cardiovascular disease?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "F4",
    "context": ""
  },
  {
    "column": "F4r14",
    "description": "F4r14: Peer-to-peer online communities (e.g. SERMO, Doximity, etc.) - From which sources would you be most receptive to receiving information on new treatments for cardiovascular disease?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "F4",
    "context": ""
  },
  {
    "column": "F4r15",
    "description": "F4r15: CDC website / newsletters - From which sources would you be most receptive to receiving information on new treatments for cardiovascular disease?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "F4",
    "context": ""
  },
  {
    "column": "F4r16",
    "description": "F4r16: Epocrates / Medscape or other PDA email services - From which sources would you be most receptive to receiving information on new treatments for cardiovascular disease?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "F4",
    "context": ""
  },
  {
    "column": "F4r17",
    "description": "F4r17: E-mails from pharmaceutical manufacturers - From which sources would you be most receptive to receiving information on new treatments for cardiovascular disease?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "F4",
    "context": ""
  },
  {
    "column": "F4r18",
    "description": "F4r18: General health & medical websites (i.e. uptodate.com, webmd.com) - From which sources would you be most receptive to receiving information on new treatments for cardiovascular disease?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "F4",
    "context": ""
  },
  {
    "column": "F4r19",
    "description": "F4r19: Peer-reviewed, published clinical study results - From which sources would you be most receptive to receiving information on new treatments for cardiovascular disease?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "F4",
    "context": ""
  },
  {
    "column": "F4r20",
    "description": "F4r20: Branded drug websites - From which sources would you be most receptive to receiving information on new treatments for cardiovascular disease?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "F4",
    "context": ""
  },
  {
    "column": "F4r21",
    "description": "F4r21: Other - From which sources would you be most receptive to receiving information on new treatments for cardiovascular disease?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "F4",
    "context": ""
  },
  {
    "column": "F7r1",
    "description": "F7r1: Leqvio - In the past 3 months, approximately how many times have you been visited by a pharmaceutical representative specifically from … Please think only about those representatives with whom you have some type of interaction, whether it is signi",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "F7",
    "context": ""
  },
  {
    "column": "F7r2",
    "description": "F7r2: Nexletol/Nexlizet - In the past 3 months, approximately how many times have you been visited by a pharmaceutical representative specifically from … Please think only about those representatives with whom you have some type of interaction, whether",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "F7",
    "context": ""
  },
  {
    "column": "F7r3",
    "description": "F7r3: Repatha - In the past 3 months, approximately how many times have you been visited by a pharmaceutical representative specifically from … Please think only about those representatives with whom you have some type of interaction, whether it is sign",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "F7",
    "context": ""
  },
  {
    "column": "F8r1c1",
    "description": "F8r1c1: # Leqvio interactions primarily focused on … - Clinical information (e.g., treatment attributes, medical references) - Of your interactions with a pharmaceutical representative in the past three months, approximately how many of those conversati",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "F8",
    "context": ""
  },
  {
    "column": "F8r1c2",
    "description": "F8r1c2: # Nexletol/ Nexlizet interactions primarily focused on … - Clinical information (e.g., treatment attributes, medical references) - Of your interactions with a pharmaceutical representative in the past three months, approximately how many of thos",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "F8",
    "context": ""
  },
  {
    "column": "F8r1c3",
    "description": "F8r1c3: # Repatha interactions primarily focused on … - Clinical information (e.g., treatment attributes, medical references) - Of your interactions with a pharmaceutical representative in the past three months, approximately how many of those conversat",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "F8",
    "context": ""
  },
  {
    "column": "F8r2c1",
    "description": "F8r2c1: # Leqvio interactions primarily focused on … - Administrative information (e.g., reimbursement, logistics) - Of your interactions with a pharmaceutical representative in the past three months, approximately how many of those conversations primar",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "F8",
    "context": ""
  },
  {
    "column": "F8r2c2",
    "description": "F8r2c2: # Nexletol/ Nexlizet interactions primarily focused on … - Administrative information (e.g., reimbursement, logistics) - Of your interactions with a pharmaceutical representative in the past three months, approximately how many of those conversa",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "F8",
    "context": ""
  },
  {
    "column": "F8r2c3",
    "description": "F8r2c3: # Repatha interactions primarily focused on … - Administrative information (e.g., reimbursement, logistics) - Of your interactions with a pharmaceutical representative in the past three months, approximately how many of those conversations prima",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "F8",
    "context": ""
  },
  {
    "column": "F8r3c1",
    "description": "F8r3c1: # Leqvio interactions primarily focused on … - Other - Of your interactions with a pharmaceutical representative in the past three months, approximately how many of those conversations primarily focused on each of the following?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "F8",
    "context": ""
  },
  {
    "column": "F8r3c2",
    "description": "F8r3c2: # Nexletol/ Nexlizet interactions primarily focused on … - Other - Of your interactions with a pharmaceutical representative in the past three months, approximately how many of those conversations primarily focused on each of the following?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "F8",
    "context": ""
  },
  {
    "column": "F8r3c3",
    "description": "F8r3c3: # Repatha interactions primarily focused on … - Other - Of your interactions with a pharmaceutical representative in the past three months, approximately how many of those conversations primarily focused on each of the following?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "F8",
    "context": ""
  },
  {
    "column": "F12r1",
    "description": "F12r1: Office-based / out-patient setting - Approximately what % of your professional time is spent in each of the following settings?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "F12",
    "context": ""
  },
  {
    "column": "F12r2",
    "description": "F12r2: Hospital / in-patient setting - Approximately what % of your professional time is spent in each of the following settings?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "F12",
    "context": ""
  },
  {
    "column": "F12r3",
    "description": "F12r3: Clinic setting - Approximately what % of your professional time is spent in each of the following settings?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "F12",
    "context": ""
  },
  {
    "column": "F12r4",
    "description": "F12r4: Performing procedures (e.g., in Cath lab) - Approximately what % of your professional time is spent in each of the following settings?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "F12",
    "context": ""
  },
  {
    "column": "F12r97",
    "description": "F12r97: Other - Approximately what % of your professional time is spent in each of the following settings?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "F12",
    "context": ""
  },
  {
    "column": "F20a",
    "description": "F20a: Approximately how many miles away is the closest academic hospital to your primary practice? Please enter the closest whole number. If it is less than a mile, please enter 0.",
    "level": "parent",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "NA",
    "context": ""
  },
  {
    "column": "F20b",
    "description": "F20b: Approximately how many miles away is the closest alternative site of care to your primary practice? Please enter the closest whole number. If it is less than a mile, please enter 0.",
    "level": "parent",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "NA",
    "context": ""
  },
  {
    "column": "F21r1",
    "description": "F21r1: Physicians - Including yourself, how many of each of the following types of healthcare professionals are in your primary practice?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "F21",
    "context": ""
  },
  {
    "column": "F21r2",
    "description": "F21r2: Nurses or Medical Assistants - Including yourself, how many of each of the following types of healthcare professionals are in your primary practice?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "F21",
    "context": ""
  },
  {
    "column": "F21r3",
    "description": "F21r3: Nurse Practitioners/Physicians Assistants - Including yourself, how many of each of the following types of healthcare professionals are in your primary practice?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "F21",
    "context": ""
  },
  {
    "column": "F21r4",
    "description": "F21r4: Administrative Staff - Including yourself, how many of each of the following types of healthcare professionals are in your primary practice?",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "F21",
    "context": ""
  },
  {
    "column": "Resp_Valr1",
    "description": "Resp_Valr1: ttinput_1 (G2r1) - Responses value code for Questions.",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "Resp_Val",
    "context": ""
  },
  {
    "column": "Resp_Valr2",
    "description": "Resp_Valr2: ttinput_2 (G2r2) - Responses value code for Questions.",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "Resp_Val",
    "context": ""
  },
  {
    "column": "Resp_Valr3",
    "description": "Resp_Valr3: ttinput_3 (G2r3) - Responses value code for Questions.",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "Resp_Val",
    "context": ""
  },
  {
    "column": "Resp_Valr4",
    "description": "Resp_Valr4: ttinput_4 (G2r5) - Responses value code for Questions.",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "Resp_Val",
    "context": ""
  },
  {
    "column": "Resp_Valr5",
    "description": "Resp_Valr5: ttinput_5 (G2r4) - Responses value code for Questions.",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "Resp_Val",
    "context": ""
  },
  {
    "column": "Resp_Valr6",
    "description": "Resp_Valr6: ttinput_6 (G2r6) - Responses value code for Questions.",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "Resp_Val",
    "context": ""
  },
  {
    "column": "Resp_Valr7",
    "description": "Resp_Valr7: ttdemo_1 (specialty_cardiologist) - Responses value code for Questions.",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "Resp_Val",
    "context": ""
  },
  {
    "column": "Resp_Valr8",
    "description": "Resp_Valr8: ttdemo_1 (specialty_endocrinologist) - Responses value code for Questions.",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "Resp_Val",
    "context": ""
  },
  {
    "column": "Resp_Valr9",
    "description": "Resp_Valr9: ttdemo_1 (specialty_lipidologist) - Responses value code for Questions.",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "Resp_Val",
    "context": ""
  },
  {
    "column": "Resp_Valr10",
    "description": "Resp_Valr10: ttdemo_1 (specialty_neurologist) - Responses value code for Questions.",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "Resp_Val",
    "context": ""
  },
  {
    "column": "Resp_Valr11",
    "description": "Resp_Valr11: ttdemo_1 (specialty_nppa) - Responses value code for Questions.",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "Resp_Val",
    "context": ""
  },
  {
    "column": "Resp_Valr12",
    "description": "Resp_Valr12: ttdemo_1 (specialty_pcp) - Responses value code for Questions.",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "Resp_Val",
    "context": ""
  },
  {
    "column": "Resp_Valr13",
    "description": "Resp_Valr13: ttdemo_2 (urban_urban) - Responses value code for Questions.",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "Resp_Val",
    "context": ""
  },
  {
    "column": "Resp_Valr14",
    "description": "Resp_Valr14: ttdemo_2 (urban_suburban) - Responses value code for Questions.",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "Resp_Val",
    "context": ""
  },
  {
    "column": "Resp_Valr15",
    "description": "Resp_Valr15: ttdemo_2 (urban_rural) - Responses value code for Questions.",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "Resp_Val",
    "context": ""
  },
  {
    "column": "Resp_Valr16",
    "description": "Resp_Valr16: ttdemo_3 (practice_academic) - Responses value code for Questions.",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "Resp_Val",
    "context": ""
  },
  {
    "column": "Resp_Valr17",
    "description": "Resp_Valr17: ttdemo_3 (practice_community) - Responses value code for Questions.",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "Resp_Val",
    "context": ""
  },
  {
    "column": "Resp_Valr18",
    "description": "Resp_Valr18: ttdemo_3 (practice_comprehensive_care) - Responses value code for Questions.",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "Resp_Val",
    "context": ""
  },
  {
    "column": "Resp_Valr19",
    "description": "Resp_Valr19: ttdemo_3 (practice_other) - Responses value code for Questions.",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "Resp_Val",
    "context": ""
  },
  {
    "column": "Resp_Valr20",
    "description": "Resp_Valr20: ttdemo_3 (practice_private_group) - Responses value code for Questions.",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "Resp_Val",
    "context": ""
  },
  {
    "column": "Resp_Valr21",
    "description": "Resp_Valr21: ttdemo_3 (practice_private_solo) - Responses value code for Questions.",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "Resp_Val",
    "context": ""
  },
  {
    "column": "Resp_Valr22",
    "description": "Resp_Valr22: ttdemo_4 (gender_Male) - Responses value code for Questions.",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "Resp_Val",
    "context": ""
  },
  {
    "column": "Resp_Valr23",
    "description": "Resp_Valr23: ttdemo_4 (gender_Female) - Responses value code for Questions.",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "Resp_Val",
    "context": ""
  },
  {
    "column": "WinSegProbr1",
    "description": "WinSegProbr1: Winning segment Probabilty Value",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "WinSegProb",
    "context": ""
  }
]